Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children

Abstract

BACKGROUND: Typhi is an increasing public health threat in sub-Saharan Africa. METHODS: We conducted a phase 3, double-blind trial in Blantyre, Malawi, to assess the efficacy of Vi polysaccharide typhoid conjugate vaccine (Vi-TCV). We randomly assigned children who were between 9 months and 12 years of age, in a 1:1 ratio, to receive a single dose of Vi-TCV or meningococcal capsular group A conjugate (MenA) vaccine. The primary outcome was typhoid fever confirmed by blood culture. We report vaccine efficacy and safety outcomes after 18 to 24 months of follow-up. RESULTS: The intention-to-treat analysis included 28,130 children, of whom 14,069 were assigned to receive Vi-TCV and 14,061 were assigned to receive the MenA vaccine. Blood culture-confirmed typhoid fever occurred in 12 children in the Vi-TCV group (46.9 cases per 100,000 person-years) and in 62 children in the MenA group (243.2 cases per 100,000 person-years). Overall, the efficacy of Vi-TCV was 80.7% (95% confidence interval [CI], 64.2 to 89.6) in the intention-to-treat analysis and 83.7% (95% CI, 68.1 to 91.6) in the per-protocol analysis. In total, 130 serious adverse events occurred in the first 6 months after vaccination (52 in the Vi-TCV group and 78 in the MenA group), including 6 deaths (all in the MenA group). No serious adverse events were considered by the investigators to be related to vaccination. CONCLUSIONS: Among Malawian children 9 months to 12 years of age, administration of Vi-TCV resulted in a lower incidence of blood culture-confirmed typhoid fever than the MenA vaccine. (Funded by the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT03299426.).

Shown for reading. Its publisher allows quoting it, not republishing it.

References 35

1. 1.

   Global Burden of Disease Collaborative Network. GBD 2020 Cause and Risk Summaries: Typhoid fever — level 4 cause. Seattle, United States: Institute for Health Metrics and Evaluation (IHME). 2020; Available from: http://www.healthdata.org/results/gbd_summaries/2019/typhoid-fever-level-4-cause

   Not in our library

2. 2.
   The burden of typhoid fever in low- and middle-income countries: A meta-regression approach · 2017

   No notice
3. 3.
   Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study · 2017

   No notice
4. 4.
   Population-Based Incidence of Typhoid Fever in an Urban Informal Settlement and a Rural Area in Kenya: Implications for Typhoid Vaccine Use in Africa · 2012

   No notice
5. 5.

   Meiring JE, Patel P, Patel P, Gordon MA. Typhoid conjugate vaccines: making vaccine history in Africa. Expert Review of Vaccines2018;17(8):673–676.

   Not in our library10.1080/14760584.2018.1496825

6. 6.

   Wong VK, Holt KE, Okoro C, Molecular surveillance identifies multiple transmissions of typhoid in West Africa. PLoS Negl Trop Dis2016;10(9):1–22.

   Not in our library10.1371/journal.pntd.0004781

7. 7.

   Wong VK, Baker S, Pickard DJ, Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events. Nat Genet2015;47(6):632–9.

   Not in our library10.1038/ng.3281

8. 8.
   A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid · 2018

   No notice
9. 9.
   Rapid Emergence of Multidrug Resistant, H58-Lineage Salmonella Typhi in Blantyre, Malawi · 2015

   No notice
10. 10.

    Olgemoeller F, Waluza JJ, Zeka D, Intestinal perforations associated with a high mortality and frequent complications during an epidemic of multidrug-resistant typhoid fever in Blantyre, Malawi. Clin Infect Dis2020;71(Suppl 2):S96–101.

    Not in our library10.1093/cid/ciaa405

11. 11.

    Feasey NA, Masesa C, Jassi C, Three epidemics of invasive multidrug-resistant Salmonella bloodstream infection in Blantyre, Malawi, 1998–2014. Clin Infect Dis 2015;61(suppl 4):S363–71.

    Not in our library10.1093/cid/civ691

12. 12.
    Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998–2016): a surveillance study · 2017

    No notice
13. 13.

    Mutai WC, Muigai AWT, Waiyaki P, Kariuki S. Multi-drug resistant Salmonella enterica serovar Typhi isolates with reduced susceptibility to ciprofloxacin in Kenya. BMC Microbiol2018;18(1):4–8.

    Not in our library10.1186/s12866-018-1332-3

14. 14.

    Tack B, Phoba MF, Van Puyvelde S, Salmonella Typhi from blood cultures in the Democratic Republic of the Congo: a 10-year surveillance. Clin Infect Dis2019;68(Suppl 2):S130–7.

    Not in our library10.1093/cid/ciy1116

15. 15.
    Emergence of an Extensively Drug-Resistant Salmonella enterica Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-Generation Cephalosporins · 2018

    No notice
16. 16.

    Burki T. Typhoid conjugate vaccine gets WHO prequalification. Lancet Infect Dis 2018;18(3):258.

    Not in our library10.1016/s1473-3099(18)30088-4

17. 17.
    Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal · 2019

    No notice
18. 18.

    Meiring JE, Gibani M, Basnyat B, The Typhoid Vaccine Acceleration Consortium (TyVAC): vaccine effectiveness study designs: accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26–27 October 2016, Oxford. Vaccine 2017;35(38):5081–8.

    Not in our library10.1016/j.vaccine.2017.08.001

19. 19.

    Theiss-Nyland K, Shakya M, Colin-Jones R, Assessing the impact of a VI-polysaccharide conjugate vaccine in preventing typhoid infections among nepalese children: a protocol for a phase III, randomized control trial. Clin Infect Dis2019;68(Suppl 2):S67–73.

    Not in our library10.1093/cid/ciy1106

20. 20.

    N’cho HS, Masunda KPE, Mukeredzi I, Notes from the Field: Typhoid Fever Outbreak — Harare, Zimbabwe, October 2017–February 2018. MMWR Morb Mortal Wkly Rep2019;68(2):44–5.

    Not in our library10.15585/mmwr.mm6802a5

21. 21.

    Kabwama SN, Bulage L, Nsubuga F, A large and persistent outbreak of typhoid fever caused by consuming contaminated water and street-vended beverages: Kampala, Uganda, January - June 2015. BMC Public Health2017;17(1):1–9. Available from:

    Not in our library10.1186/s12889-016-4002-0

22. 22.

    Meiring JE, Laurens MB, Patel P, Typhoid vaccine acceleration consortium Malawi: A Phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi. Clin Infect Dis2019;68(Suppl 2):S50–8.

    Not in our library10.1093/cid/ciy1103

23. 23.

    Meiring JE, Sambakunsi R, Moyo E, Community engagement before initiation of typhoid conjugate vaccine trial in schools in two urban townships in Blantyre, Malawi: Experience and lessons. Clin Infect Dis2019;68(Suppl 2):S146–53.

    Not in our library10.1093/cid/ciy1110

24. 24.

    The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 10.0. 2020 [cited 2020 Dec 9];1–128. Available from: https://eucast.org/

    Not in our library

25. 25.

    Klugman KP, Koornhof HJ, Schneerson R, Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet1987;330(8569):1165–9.

    Not in our library10.1016/s0140-6736(87)91316-x

26. 26.

    Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine1996;14(5):435–8.

    Not in our library10.1016/0264-410x(95)00186-5

27. 27.

    Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 2007;25(45):7848–57.

    Not in our library10.1016/j.vaccine.2007.08.027

28. 28.

    WHO. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec2008;83(6):49–59.

    Not in our library

29. 29.

    Feasey NA, Masesa C, Jassi C, Three epidemics of invasive multidrug-resistant salmonella bloodstream infection in Blantyre, Malawi, 1998–2014. Clin Infect Dis2015;61(Suppl 4):S363–71.

    Not in our library10.1093/cid/civ691

30. 30.

    Bilcke J, Antillón M, Pieters Z, Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. Lancet Infect Dis2019;19(7):728–39.

    Not in our library10.1016/s1473-3099(18)30804-1

31. 31.

    Olaru ID, Mtapuri-Zinyowera S, Feasey N, Ferrand RA, Kranzer K. Typhoid Vi-conjugate vaccine for outbreak control in Zimbabwe. Lancet Infect Dis2019;19(9):930. Available from:

    Not in our library10.1016/s1473-3099(19)30425-6

32. 32.

    Malawi Population-based HIV Impact Assessment (PHIA). Available from: https://phia.icap.columbia.edu/

    Not in our library

33. 33.

    Kim JH, Im J, Parajulee P, A systematic review of typhoid fever occurrence in Africa. Clin Infect Dis 2019;69(Suppl 6):S492–8.

    Not in our library10.1093/cid/ciz525

34. 34.

    Levine MM, Farag TH. Invasive salmonella infections and HIV in northern Tanzania. Clin Infect Dis2011;52(3):349–51.

    Not in our library10.1093/cid/ciq109

35. 35.

    Carey ME, Jain R, Yousuf M, Maes M, Dyson ZA. Spontaneous emergence of azithromycin resistance in independent lineages of Salmonella Typhi in Northern India. Clin Infect Dis. In Press.

    Not in our library10.1093/cid/ciaa1773

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.